ABVX vs ATOS: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABVX and ATOS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABVX and ATOS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Abivax SA is a French clinical-stage biopharmaceutical company listed on Nasdaq via a sponsored ADR (ABVX). Its lead and effectively sole value driver is obefazimod (formerly ABX464), a first-in-class oral miR-124 enhancer being developed for inflammatory bowel disease. In 2025 and 2026 the pivotal Phase 3 ABTECT program in moderate-to-severe ulcerative colitis reported positive results across both induction trials and the maintenance trial, with the 50 mg dose showing clinical remission around 51% at Week 44 versus roughly 10% for placebo. Management has guided toward a U.S. FDA new drug application filing in late 2026, with a Phase 2b Crohn's disease readout expected around mid-2027.

Full ABVX guide

Atossa Therapeutics, Inc. (ATOS) is a clinical-stage biopharmaceutical company focused on breast cancer. Its lead investigational asset is (Z)-endoxifen, an oral active metabolite of tamoxifen being studied for ER+/HER2- breast cancer and for reducing mammographic breast density. Key programs include the EVANGELINE Phase 2 trial evaluating (Z)-endoxifen with ovarian function suppression as a neoadjuvant therapy in premenopausal patients, which the company streamlined in late 2025 to prioritize near-term, NDA-enabling activities in 2026, and the KARISMA endoxifen study, whose results in healthy premenopausal women were published in 2026. Atossa has no approved products and generates no meaningful product revenue.

Full ATOS guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABVX drivers: Positive Phase 3 obefazimod data; Path to an FDA filing.
• ATOS drivers: (Z)-endoxifen as the central value driver; EVANGELINE and pipeline progression.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. For ATOS, aTOS carries the full spectrum of clinical-stage biotech risk.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABVX if you believe its drivers more; ATOS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABVX and ATOS guides.

ABVX. Abivax has effectively no product revenue and posts large net losses, which is normal for a clinical-stage biotech funding pivotal trials rather than a warning sign on its own. Traditional earnings multiples do not apply; the market instead values the probability-weighted potential of obefazimod reaching and selling in the market. The mid-2026 capital raise materially extended the runway and reduced near-term financing risk.

ATOS. These figures are qualitative and directional, not exact. A clinical-stage biotech like Atossa is valued on the perceived potential of its pipeline rather than on current earnings, because it has no product revenue and runs at a loss by design. The metric that matters most is cash runway: how long existing funds can sustain trials before the company must raise more capital, typically by issuing shares. Always confirm the latest reported cash, burn rate, and share count in Atossa's most recent SEC filings before making any decision.

Headline figures (approximate, July 2026): ABVX shows market cap ~$7-8B, product revenue (ttm) ~negligible (pre-commercial), net loss (fy2025) ~EUR 336M, r&d expense (fy2025) ~EUR 178M; ATOS shows product revenue None. Atossa is pre-revenue with no approved product; it earns no meaningful product sales., cash position Held cash and equivalents in the low tens of millions of dollars as of early 2026; the company is debt-free but disclosed a going concern warning., cash runway Limited. Quarterly cash burn is in the high single-digit millions, implying only a few quarters of runway before additional financing is likely needed., lead program (Z)-endoxifen for ER+/HER2- breast cancer, with the EVANGELINE Phase 2 trial and supporting studies still in clinical development..

ABVX and ATOS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABVX and ATOS exposure against your real portfolio. It is not an investment adviser.